...
首页> 外文期刊>Nephrology. >Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients.
【24h】

Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients.

机译:肾素-血管紧张素系统抑制剂对腹膜透析患者腹膜纤维化的预防作用。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: Long-term peritoneal dialysis (PD) may lead to peritoneal fibrosis and ultrafiltration failure. It had been demonstrated that the renin-angiotensin system (RAS) plays a key role in the regulation of peritoneal function in rats on PD. We investigated the effects of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) on long-term PD patients. METHODS: We analyzed data from 66 patients treated with PD therapy at our centre for at least 12 months retrospectively, during which time at least two peritoneal equilibration tests (PET) were performed. Thirty-eight patients were treated with ACE/angiotensin II (AII) inhibitors (ACE/ARB group); the other 28 received none of the above drugs during the entire follow up (control group). The expression of fibronectin, transforming growth factor-beta1 (TGF-beta1), Aquaporin1 (AQP1) and vascular endothelial growth factor (VEGF) in the overnight effluent were examined by enzyme-linked immunosorbent assay. RESULTS: The demographic data of the two groups showed no difference during the study. No difference between the groups was found with respect to residual renal function (RRF) at the start for both groups by the end of follow up, decreased in the vast majority of patients from both groups (P = 0.014). After 12 months, a significant difference in ultrafiltration was found between the two groups: in the control group it had decreased, while it had not changed in the ACE/ARB group (P < 0.05). In comparison with the baseline level, expression of fibronectin, TGF-beta1 and VEGF in dialysate effluent were significantly increased except for AQP1 in the control group (P < 0.05), but not in the ACE/ARB group (P > 0.05). CONCLUSION: The findings suggest that ACE/AII inhibitors appeared to have a slower rate of decline in ultrafiltration and RRF, effectively protect against peritoneal fibrosis in long-term peritoneal dialysis. Long-term follow up seems to be required to draw more conclusions.
机译:目的:长期腹膜透析(PD)可能导致腹膜纤维化和超滤失败。已经证明,肾素-血管紧张素系统(RAS)在PD大鼠的腹膜功能调节中起关键作用。我们研究了血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)对长期PD患者的影响。方法:我们回顾性分析了来自我们中心至少66个月接受PD治疗的66例患者的数据,在此期间至少进行了两次腹膜平衡测试(PET)。 38例患者接受了ACE /血管紧张素II(AII)抑制剂治疗(ACE / ARB组);在整个随访过程中,其他28例均未接受上述药物治疗(对照组)。通过酶联免疫吸附法检测了过夜分泌物中纤连蛋白,转化生长因子-β1(TGF-β1),水通道蛋白1(AQP1)和血管内皮生长因子(VEGF)的表达。结果:两组的人口统计学数据在研究期间均无差异。在随访结束时,两组在开始时均未发现残余肾功能(RRF)的差异,两组中的绝大多数患者均降低了残余肾功能(P = 0.014)。 12个月后,两组之间的超滤存在显着差异:对照组中的超滤有所降低,而ACE / ARB组中的超滤却没有改变(P <0.05)。与基线水平相比,除AQP1外,对照组的透析液中纤连蛋白,TGF-β1和VEGF的表达均显着增加(P <0.05),而ACE / ARB组则没有(P> 0.05)。结论:研究结果表明,ACE / AII抑制剂在长期腹膜透析中似乎具有较慢的超滤和RRF下降速率,可有效预防腹膜纤维化。为了得出更多结论,似乎需要长期跟踪。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号